Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04423159 |
Other study ID # |
CHOVAXIM |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
October 16, 2016 |
Est. completion date |
October 31, 2020 |
Study information
Verified date |
July 2022 |
Source |
Centre for Infectious Disease Research in Zambia |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of the study is to find out if individuals who received first and second dose of
Oral Cholera Vaccine (OCV) in Lukanga Swamps, Central Province of Zambia have developed
protection against future attacks to cholera. The investigators also want to investigate
whether vitamin A deficiency and being HIV positive increases the chances of suffering from
cholera.
Description:
Cholera is caused by toxigenic strains of Vibrio cholerae O1 and O139 and is characterised by
sudden onset of acute watery diarrhoea that can lead to severe dehydration and ultimately
death if not treated. Zambia, has continued to experience cholera outbreaks in several parts
of the country. In order to curb the disease outbreaks, the World Health Organisation (WHO)
recommended introducing cholera vaccination as a supplementary cholera control measure
together with other prevention and control strategies, in endemic areas as well as in other
places at risk for cholera outbreaks. OCV has recently been introduced to Zambia where a
large population was vaccinated with 1 dose of Shanchol®, and about 6 months later over 70%
individuals traced to receive a second dose.
Considering the annual outbreaks of cholera in Zambia, there is urgent need to determine
whether Shanchol® is able to elicit a sufficient and specific immunological response in
individuals who received OCV in Zambia. This study will also help the investigator understand
whether there are immune response differences based on genetics and may indicate whether some
people may need more vaccine regimens than others.
Objective 1: To profile cholera specific antibody status of a population at risk of cholera
before and after receiving 1st and 2nd dose of shanchol ® oral cholera vaccine (OCV)
Objective 2: To profile and characterize cholera specific B and T lymphocyte phenotypes among
the immunized Zambians Objective 3: Develop and evaluate a non-invasive proxy measure of OCV
immune responses Objective 4: To measure the protective value of immunizing HIV-infected
individuals through measurement of the neutralization capabilities OCV generated antibodies
Objective 5: To assess the impact of ABO blood groups on cholera antibody generation